Hard to Believe Dementia Effects Found
Brad Stanfield
7 jul 2025
Mindsip insights from this episode:
Reduce dementia risk with SGLT2 inhibitors
The same nine-year study found that patients using SGLT2 inhibitors had a 43% lower risk of dementia compared to those on other treatments.
Address insulin resistance to combat Alzheimer's disease
Alzheimer's disease and type 2 diabetes share a key mechanism where cells lose the ability to respond properly to insulin, which regulates blood sugar.
Prepare for high dementia risk in Americans over 55
A recent analysis projects that up to 42% of Americans over the age of 55 will eventually develop dementia, a much higher estimate than previously thought.
Reduce dementia risk with GLP-1 drugs for type 2 diabetes
A recent nine-year study of patients with type 2 diabetes found that those taking a GLP-1 agonist had a 33% lower risk of developing dementia.
Utilize GLP-1 drugs to combat brain inflammation and oxidative stress
GLP-1 agonists like Ozempic can cross the blood-brain barrier to directly provide an anti-inflammatory effect and combat oxidative stress within the brain.
Monitor Alzheimer's trials for semaglutide outcomes by 2026
Large clinical trials called Evoke and Evoke plus are currently testing semaglutide on people with early-stage Alzheimer's, with results expected in 2026.
Block glucose reabsorption with SGLT2 inhibitors to eliminate excess sugar
SGLT2 inhibitors work by blocking the kidneys from reabsorbing glucose, causing excess sugar to be filtered out and removed from the body through urine.
More from
Brad Stanfield
You also might be interested in
Ketosis (Fasting/Ketogenic Diet) accelerates Cancer Growth - New Study
Soda & Cancer Death: The Link Found in Multiple Large Studies
Early Detection Saved Me: Maria Menounos on Becoming the CEO of Your Health
Linus Pauling: Vindicated by New Evidence?
One Fat Can Prevent Dementia — If You Eat It Long-term
